Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Royal Bank of Canada (RY) Price & Performance

Incyte CorporationTrade
Royal Bank of CanadaTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Royal Bank of Canada — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Royal Bank of Canada trades at $210.44 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 11.9× Incyte Corporation's market cap, and Royal Bank of Canada pays a 2.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYRY
Market Cap
$24.54B$292.32B
Sector
HealthFinancials
52-Week High
$129.93$217.87
52-Week Low
$81.61$134.80
Enterprise Value
$20.04B
Dividend Yield
2.37%

Returns comparison

Trailing returns across standard periods

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Royal Bank of Canada

Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.

Read more on RY